

Amendments to the Specification

Please add the following "Related Applications" paragraph after the Title at page 1, line 4:

RELATED APPLICATIONS

This application is the U.S. National Stage of International Application No. PCT/JP2005 /02771, filed on February 22, 2005 in Japanese, and claims priority under 35 U.S.C. § 119 or 365 to Japanese Application No. 2004-294740, filed October 7, 2004.

Please replace the paragraph at page 16, lines 21 through 25 with the following amended paragraph:

~~Naftiomate~~ Tolnaftate, clotrimazole, cloconazole hydrochloride, isoconazole nitrate, sulconazole nitrate, fluconazole, itraconazole, miconazole, ketoconazole, thioconazole, bifonazole, griseofulvin, siccanin, trichomycin, pimarinic, amphotericin B, nystatin, pyrrolnitrin, exalamide, tolclate, variotin, haloprogin, phenyliodo undecyanoate, flucytosine, terbinafine hydrochloride, naftifine, octpirox, ciclopirox, olamine, acyclovir, idoxuridine, etc.

Please replace the paragraph at page 19, lines 23 through 24 with the following amended paragraph:

Trypsin, papain, protease, serrapeptase, lysozyme, bromelain, streptokinase, plasmin, urokinase, α -chymotrypsin, serratio peptidase, semi-alkaline ~~peptidase~~ protease, lysozyme chloride, etc.

Please replace the paragraph at page 20, lines 7 through 8 with the following amended paragraph:

Experiments on skin permeability of HAPs with different particle sizes were carried out using the method of Fujii ~~(2)~~ (1) with modification.

Please replace the paragraph at page 21, lines 11 through 14 with the following amended paragraph:

Eight-week old female golden hamsters were used in this experiment. The animals were sacrificed by decapitation to avoid influences of anesthesia. Immediately, oral mucosa was excised. ~~The oral mucosa was then~~ fat and muscle coat were then removed from the excised oral mucosa ~~so as to include mucosa to basal membrane~~ with considerable care not to let it dry.

Please replace the paragraph at page 25, lines 21 through 24 with the following amended paragraph:

The solutions were sampled from the receptor phase 1, 3, 6, 12, and 24 hours after the start of study. The concentrations of drugs in the solutions were quantified by high performance liquid chromatography to determine the amounts of drugs permeated through the skin mucosa. The result is shown in Table 8; the values represent skin permeability in $\mu\text{g}/\text{cm}^2$.

Please replace the paragraph at page 27, lines 4 through 10 with the following amended paragraph:

When compared with the Controlled study 5-2 composition containing no HAP, the skin permeability of the Study 5-1 composition which has a HAP content of 0.1 weight percent based on the drug was markedly enhanced; and the skin permeability was significantly enhanced in the compositions of Studies 5-3 to 5-6, in which the HAP content based on the drug ranged from 10 to 200 weight percent (see ~~Tables 4 and 5~~ Table 8). The skin permeability was particularly high in the Study 5-4 composition, which was prepared by pre-mixing the drug and HAP with a stirrer and then combining the mixture with the remaining agents.